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The human ROCO proteins are a family of multi-domain proteins sharing
a conserved ROC-COR supra-domain. The family has four members: leu-
cine-rich repeat kinase 1 (LRRK1), leucine-rich repeat kinase 2 (LRRK2),
death-associated protein kinase 1 (DAPK1) and malignant fibrous histiocy-
toma amplified sequences with leucine-rich tandem repeats 1 (MASL1).
Previous studies of LRRK1/2 and DAPK1 have shown that the ROC (Ras
of complex proteins) domain can bind and hydrolyse GTP, but the cellular
consequences of this activity are still unclear. Here, the first biochemical
characterization of MASL1 and the impact of GTP binding on MASL1
complex formation are reported. The results demonstrate that MASL1,
similar to other ROCO proteins, can bind guanosine nucleotides via its
ROC domain. Furthermore, MASL1 exists in two distinct cellular com-
plexes associated with heat shock protein 60, and the formation of a low
molecular weight pool of MASL1 is modulated by GTP binding. Finally,
loss of GTP enhances MASL1 toxicity in cells. Taken together, these data
point to a central role for the ROC/GTPase domain of MASL1 in the reg-
ulation of its cellular function.
Structured digital abstract
 HSP60 and MASL1 physically interact by molecular sieving (View interaction)
 MASL1 physically interacts with HSP70 and HSP60 by anti tag coimmunoprecipitation (View interaction)
 MASL1 physically interacts with HSP60 by anti tag coimmunoprecipitation (View interaction)
Introduction
Malignant fibrous histiocytoma amplified sequences
with leucine-rich tandem repeats 1 (MASL1) is the
smallest member of the human ROCO protein family,
members of which are characterized by a conserved
supra-domain containing a Ras of complex proteins
(ROC) domain and a C-terminal of ROC (COR)
domain [1]. In addition to MASL1, this protein family
includes the leucine-rich repeat kinases 1 and 2
(LRRK1/2) and death-associated protein kinase 1
(DAPK1) (Fig. 1) [2]. All four of the human ROCO
proteins have been linked to human disease, with
LRRK2 in particular being the focus of an intense
Abbreviations
BN, blue native; COR, C-terminal of ROC; DAPK1, death-associated protein kinase 1; FACS, fluorescence-activated cell sorting; HA,
hemagglutinin; HMW, high molecular weight; HSP, heat shock protein; LMW, low molecular weight; LRRK1, leucine-rich repeat kinase 1;
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research effort due to its importance in genetic Parkin-
son’s disease as well as inflammatory bowel disease
and leprosy [3]. MASL1 was originally identified in
malignant fibrous histiocytomas and has been linked
to other forms of cancer [4–7]. It is clear that under-
standing the cellular and molecular functions of these
proteins is an important challenge in several areas of
biomedical research.
Based upon bioinformatic analyses, the ROC
domain that defines this protein family is predicted to
bind guanosine triphosphate (GTP), a property that
has been demonstrated for LRRK1, LRRK2 and
DAPK1 [8–10]. Functional and structural investiga-
tions support a role for GTP binding by the ROC
domains of these proteins as well as an involvement in
complex formation and in the control of protein func-
tion. In the case of DAPK1 and LRRK2, GTP bind-
ing has been implicated in the regulation of the kinase
activities of these proteins, although the precise mecha-
nism whereby this occurs is unclear [9,11,12]. Struc-
tural information obtained from the bacterial
Chlorobium tepidum ROCO protein suggests that the
COR domain functions as a dimerization device to
activate ROC GTPase activity [13]. Interestingly, the
C. tepidum ROCO protein and human MASL1 display
conserved domain organization, with N-terminal leu-
cine-rich repeats and a C-terminal ROC-COR bi-
domain [13].
MASL1 is unique among the human ROCO pro-
teins in not possessing a clear effector domain, either a
kinase (as is the case for LRRK1, LRRK2 and
DAPK1) or a death domain (DAPK1). No informa-
tion regarding the function or structure of this protein
is available to date. The aim of this study was there-
fore to investigate typical ROCO protein features such
as GTP binding, GTPase activity and complex forma-
tion of MASL1 as well as to identify possible binding
partners. These data demonstrate for the first time that
MASL1 is a functional GTP binding protein and that
complex formation by MASL1 is regulated in a man-
ner dependent on guanosine nucleotide binding.
Results
MASL1 is a GTP binding protein
To investigate the function of the ROC domain of
MASL1, an artificial mutation (K442A), designed to
disrupt nucleotide binding, was introduced into the
open reading of hemagglutinin (HA) tagged MASL1.
This mutation was chosen based on homology to small
GTPases and LRRK2, where it has previously been
shown to impact upon GTP binding properties [14].
The K422A mutant had no impact on steady state
expression of MASL1 (Fig. 2A). Wild type HA-tagged
MASL1 was able to bind GTP immobilized on sepha-
rose beads, an interaction that could be disrupted by a
molar excess of GTP (10 mM) (Fig. 2B). In contrast,
the predicted nucleotide binding deficient form of the
protein (K422A MASL1) was incapable of binding
GTP, confirming the importance of this residue for
GTP binding. To assess whether MASL1 is able to hy-
drolyse as well as bind GTP, a series of in vitro radio-
metric assays was carried out. As a positive control
the small GTPase RAC1 [15] was used. MASL1 (wild
type and K422A) and wild type RAC1 could be immu-
noprecipitated and eluted at similar levels (Fig. 2C).
Under the assay conditions used in this experiment,
RAC1 displayed GTPase activity whereas neither wild
type nor K442A MASL1 was able to hydrolyse GTP
above background levels (Fig. 2D,E). Based upon
these in vitro data, it is impossible to exclude the possi-
bility that MASL1 is capable of hydrolysing GTP in a
cellular context with the aid of cofactors.
Guanosine nucleotides regulate complex
formation by MASL1
Data from a number of studies investigating complex
formation by DAPK1 and LRRK2 suggest that the
human ROCO proteins form multi-component com-
plexes in a cellular context [10,16–18]. To investigate
complex formation by MASL1, size exclusion chroma-
tography (SEC) and blue native (BN) gel electrophore-
sis were applied to clarified cell lysates of HEK293T
cells overexpressing wild type and K422A HA-tagged
MASL1. These analyses revealed that wild type
MASL1 fractionates as two complexes, a low molecu-
lar weight (LMW, ~ 200 kDa) and a high molecular
weight (HMW, ~ 600 kDa) (Fig. 3A). To verify that
Fig. 1. The human ROCO protein family consists of four proteins
called LRRK1, LRRK2, DAPK1 and MASL1. Together a conserved
GTPase domain called ROC-COR, which stands for Ras of complex
proteins and C-terminal of ROC domains, characterizes these
proteins.
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the LMW peak was not a degraded product of the
HMW complex, SDS/PAGE followed by immunoblot-
ting was carried out on the two chromatographic
fractions. As shown in Fig. 3B, both peaks represent
full-length proteins. Additionally, wild type and
K422A MASL1 were analysed by SEC in the presence
of EDTA (5 mM in lysis buffer and SEC running buf-
fer to equilibrate the mobile phase), resulting in a loss
of the LMW peak (Fig. S1). These data suggest that
the observed shift in MW is due to a disruption of
nucleotide binding rather than protein misfolding or
degradation. It is notable that loss of nucleotide bind-
ing by K422A MASL1 disrupts the LMW peak specifi-
cally (Fig. 3A), while it does not impact upon
immunoreactivity at ~ 600 kDa. To examine complex
formation using an alternative approach, BN gel elec-
trophoresis was used. In agreement with the SEC data,
wild type MASL1 displayed a biphasic distribution
with a distinct band at ~ 200 kDa and a higher
molecular mass smear consistent with the ~ 600 kDa
complex observed using SEC. Disruption of nucleotide
binding again resulted in a change in apparent molecu-
lar mass, with a dramatic reduction in the intensity of
the ~ 200 kDa band (Fig. 3D). To assess whether the
loss of guanosine nucleotide binding has an impact on
the folding of MASL1, fluorescence spectra were
recorded for purified wild type and K422A variants of
the protein in the presence and absence of the denatur-
ant guanidine hydrochloride (Fig. S2). Spectra for wild
type and K422A forms of MASL1 were comparable,
and both underwent a clear shift in spectra upon expo-
sure to 6 M GdHCl suggesting that, under the condi-
tions used in the experiments described above, both
forms of MASL1 adopt a native fold.
Based upon the importance of nucleotide binding
properties on complex formation by MASL1, the
impact of GTP or GDP addition to cell lysates upon
the predilection of MASL1 to form LMW or HMW
A
D
E
B C
Fig. 2. MASL1 – a GTP binding protein. (A) Both wild type and K422A MASL1 expressed equally in HEK293T cells. (B) Overexpression of
HA-tagged MASL1 in HEK293T cells was used to determine GTP binding of MASL1. The wild type and K422A forms of the protein were
tested for binding to GTP immobilized on sepharose beads with or without a molar excess of GTP. This analysis revealed that wild type
MASL1 is a GTP binding protein and that a molar excess of GTP as well as a targeted mutation of the lysine residue at 422 disrupt GTP
binding. (C) In order to investigate the ability of MASL1 to hydrolyse GTP both forms of MASL1 and a known GTPase RAC1 were
expressed in HEK293T cells. The FLAG-tagged proteins expressed equally (a-FLAG) and could also be eluted in a very pure fashion from
FLAG-agarose beads with 150 nglL1 FLAG peptide (Coomassie). (D), (E) GTPase activity was observed over a period of 0–120 min
displaying activity only by RAC1. No GTPase activity was detected in either form of MASL1 under these experimental conditions.
Untransfected HEK293T cells, treated with transfection reagent polyethylenimine (PEI) only, were used as control samples (CON) for all
analyses.
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complexes was examined (Fig. 3C). Cell lysates, as well
as the mobile phase of the chromatography column,
were pre-loaded with 200 lM GTP or GDP. As shown
in Fig. 3C, the formation of the LMW complex was
modulated by the presence of guanosine nucleotides.
Specifically, GDP shifted the equilibrium between
A
C
D
B
Fig. 3. GTP binding properties of MASL1 regulate complex formation. (A) SEC was used to analyse whole cell lysates of MASL1
transfected HEK293T cells. Wild type MASL1 was found in two complexes, an HMW complex and an LMW complex of ~ 600 and
~ 200 kDA respectively. In contrast, K422A MASL1 was only found as an HMW complex; representative dot blots are shown. (B) Fractions
containing the HMW or LMW complexes were probed for HA showing that full-length MASL1 can be found in both. (C) To investigate the
effect of GTP/GDP upon complex formation of MASL1, cell lysates and the SEC column were incubated with 200 lM GTP or GDP prior to
analysis. No effect was seen in the K422A mutant. In contrast, wild type MASL1 complexes shifted between HMW and LMW upon GDP or
GTP treatment respectively as shown in the graphs. Ratios between HMW and LMW peaks further emphasize this shift: in untreated
conditions the ratio between HMW and LMW is 1 : 0.94; upon GDP treatment the equilibrium shifts towards HMW resulting in a ratio of
1 : 0.34; GTP treatment results in a shift towards LMW as seen by a ratio of 1 : 1.28. (D) As an alternative approach to SEC, BN PAGE also
showed that wild type MASL1 and the K422A mutant form different complexes. Data are presented as the mean of three individual
experiments  SEM.
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LMW and HMW complex towards the latter, whereas
incubation with GTP favoured formation of the LMW
form of MASL1. Neither GTP nor GDP had any
impact on the complex formed by the nucleotide bind-
ing dead form of MASL1. As the ability of MASL1 to
hydrolyse GTP is still unclear, a SEC run was carried
out in the presence of a non-hydrolysable guanosine
trinucleotide (GMppCp, Fig. S3). This reveals a simi-
lar pattern to that observed for wild type MASL1 in
the presence of GTP. Taken together, these data sug-
gest that the guanosine nucleotide binding status of
MASL1 has a major impact on complex formation by
this protein.
Heat shock protein 60 (HSP60) interacts with
MASL1
The presence of MASL1 in two cellular complexes of
~ 600 kDa and ~ 200 kDa suggests that MASL1 may
form an active complex with other proteins in the cell.
To identify such potential binding partners, HA-tagged
MASL1 protein overexpressed in HEK293T cells was
immunoprecipitated. Co-purifying proteins were iso-
lated by SDS/PAGE (Fig. 4A) and the corresponding
bands were subjected to mass spectrometry analysis
(Fig. 4B). A representative image (Fig. 4A) shows that
MASL1 (band a) was successfully immunoprecipitated
as well as additional bands representing possible inter-
actors/binding partners, which were not present in the
control condition (untransfected). Two major bands of
~ 60 and ~ 40 kDa were analysed and identified as
HSP60 and HSP70 respectively (Fig. 4B). The band at
60 kDa (band b) was identified as HSP60 and dis-
played a high correlation score (30%). The band at
40 kDa (band c) was identified as HSP70 and dis-
played a low correlation score. Due to the divergence
in the relative molecular mass of this band and the
predicted mass of HSP70, in combination with the low
correlation score, subsequent experiments focused on
HSP60. To validate these mass spectrometry findings,
the SEC fractions of HEK293T cell lysates expressing
MASL1 (either wild type or K422A) were assessed for
the presence of HSP60. These data reveal HSP60 as
being present in the same fractions as MASL1
(Fig. 5A). In co-immunoprecipitation experiments fol-
lowed by immunoblot for HSP60, MASL1 (both wild
type and mutant) was found to co-purify with HSP60
(Fig. 5B).
Cellular localization of MASL1
Given the impact of guanosine nucleotide occupancy
on complex formation by MASL1, the cellular locali-
zation of wild type and K422A MASL1 was assessed
by immunocytochemistry. To achieve this, HEK293T
cells transfected with HA-tagged wild type and K422A
forms of MASL1 were analysed by immunocytochem-
istry and confocal microscopy. Both wild type and
K422A MASL1 were expressed at similar levels and
displayed broad cytoplasmic localization (Fig. 6).
ROCO proteins have been suggested to participate in
vesicle cycling; in particular LRRK2 regulates synaptic
A B
Fig. 4. Identification of potential MASL1 interactors. HEK293T cells were transfected with both forms of MASL1 and cell lysates
immunoprecipitated with FLAG-agarose beads before being subjected to a series of washing steps with a range of NaCl and Triton X-100
concentrations (see Materials and methods). (A) MASL1 co-purifying bands, not seen in CON samples (insets a, b, c), were selected for
analysis. (B) Excised bands were subjected to MALDI-QTOF MS and identified as (a) MASL1, (b) HSP60 and (c) HSP70. While HSP60 co-
purified at the predicted molecular weight, HSP70 was found in a band with the incorrect molecular weight and a low correlation score
(~ 4%). HSP60 was found in two out of three MS experiments carried out.
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Fig. 5. Interaction of MASL1 and HSP60. (A) Fractions obtained from SEC analysis of wild type and K422A MASL1 were probed for HSP60,
showing a similar distribution to MASL1 with no HSP60 present in the LMW fraction. Representative dot-blot images also show that HSP60
expression follows the same pattern as MASL1. (B) To verify these findings we also analysed HSP60 co-immunoprecipitation with FLAG-
tagged MASL1. Wild type and K422A MASL1 co-immunoprecipitated HSP60 at similar levels. Data are presented as the mean of three
individual experiments  SEM.
Fig. 6. Cytosolic localization of MASL1.
Wild type and K422A MASL1 expressed at
equal levels in HEK293T cells. Despite the
lysine mutation at 422 no changes in the
expression pattern were observed. Co-
expression with the cytoskeletal marker
phalloidin, the mitochondrial marker
complex V and the lysosomal marker
LAMP1 were analysed. No apparent co-
localization was observed with the
markers used in this study. Scale bar,
10 lm.
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vesicle trafficking and LRRK1 epidermal growth fac-
tor receptor trafficking [19–21]. To determine whether
MASL1 preferentially associates with any specific
organelles/structures within the cell, co-localization
studies were performed with the lysosomal marker
LAMP1, the cytoskeletal marker phalloidin and com-
plex V as a marker of mitochondria. Although both
forms of MASL1 occasionally co-localized with the
lysosomal marker LAMP1, no consistent co-localiza-
tion with the markers used in this study was observed
(Fig. 6).
Cytotoxicity of MASL1 in HEK293T cells
Overexpression of the ROCO proteins DAPK1 and
LRRK2 is associated with cytotoxicity in cellular mod-
els [22–24]. In common with both of these proteins,
MASL1 has been implicated in cancer suggesting a pos-
sible role in the control of cell death or proliferation. To
examine cellular toxicity of MASL1 upon transfection
in HEK293T cells, two approaches were used: a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay and fluorescence-activated cell sorting
(FACS) to allow identification of viable, necrotic and
apoptotic cells. Expression of wild type MASL1 resulted
in a significant decrease in viable cells compared with
controls, an effect that was exacerbated by the
expression of the nucleotide binding dead form of the
protein (Fig. 7). To confirm these observations with an
independent technique, FACS analysis of cells transfect-
ed with MASL1 was carried out. Approximately 5000
transfected cells were analysed per sample (n = 3 per
genotype). Untransfected control cells were used to set
up gating of transfected cells (p4) (Fig. S4). Analysis of
MASL1 positive cells showed a similar trend towards
increased cell death in K422A MASL1 transfected cells
(p4) as observed with the MTT assay (Fig. 8). This
increase predominantly consisted of necrotic cells
(Fig. 8B,C). No difference of either apoptosis or necro-
sis could be observed in the untransfected cell popula-
tion (p3) or with control cells (Fig. S4).
Discussion
This study provides an insight into the biology of
MASL1, the smallest member of the human ROCO
protein family. The data presented here demonstrate
that MASL1 possesses an ROC domain that is capable
of binding GTP, and that guanosine binding properties
of MASL1 are important for complex formation and
for the cytotoxic properties of this protein.
Two approaches were used to determine the GTP
binding properties of MASL1. First, a competitive
GTP binding assay in which MASL1 was incubated
with or without GTP free in solution along with
immobilized GTP on sepharose beads showed that the
wild type protein is able to bind GTP and that this
interaction is competed away by incubation with a
molar excess of GTP. Second, a targeted genetic dis-
ruption of a conserved lysine (K422) important for
nucleotide binding identified by sequence alignment
with DAPK1 and LRRK2 resulted in complete loss of
GTP binding. These data are consistent with results
obtained for the other human ROCO proteins.
Protein binding to GTP immobilized on sepharose
beads is a useful technique to assess the ability of
MASL1 to bind GTP; however, it does not provide any
information about the ability of this protein to
hydrolyse GTP. MASL1 GTPase activity was therefore
assessed using previously published protocols [14].
Using the small GTPase RAC1 as a positive control,
FLAG-tagged MASL1 free in solution displayed no
detectable GTPase activity above background. While
these findings suggest that MASL1 has very low endog-
enous GTPase activity, it is possible that cofactors such
as GTPase activating proteins are required for MASL1
to hydrolyse GTP at detectable rates in vitro.
The loss of GTP binding has the potential to disrupt
the stability of MASL1; however, analysis of steady
state expression levels of the wild type and K422A
forms of the protein demonstrated that both forms
have equivalent expression levels, suggesting that loss
of nucleotide binding does not result in a major alter-
ation in folding. This is further supported by SEC
Fig. 7. Increased cellular toxicity in the GTP dead form of MASL1.
Expression of wild type and K422A MASL1 resulted in significantly
increased cellular toxicity compared with untransfected control
cells. In addition, cellular toxicity was more severe in the GTP dead
form of the protein compared with wild type MASL1. Data are
presented as the mean of three individual experiments  SEM.
One-way ANOVA followed by the Bonferroni post hoc test was
used to determine potential statistical significance, with P values
≤ 0.05 considered significant.
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Fig. 8. Cellular toxicity upon MASL1
expression. HEK293T cells were
transfected with wild type and K422A
MASL1. A cell death staining kit detecting
apoptotic, live and necrotic cells enabled
the analysis of cell death via FACS. Cells
were sorted by size and complexity prior
to separating untransfected (p3) from
MASL1 transfected (p4) cells. (A) Wild
type MASL1 transfection resulted in ~ 3%
and ~ 5% necrotic cells in untransfected
or transfected cells respectively. (B)
K422A MASL1 also led to ~ 3% necrotic
cells in the untransfected cell population
but resulted in ~ 10% necrotic cells in
K422A positive cells. (C) FACS analysis of
n = 3 per wild type and K422A MASL1
transfected cells displayed as the average
of three experiments in
percentage  SEM.
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analysis in the presence of EDTA (Fig. S1), which
demonstrates that disruption of nucleotide binding
results in similar changes in complex formation of
MASL1 as observed for the K422A mutant. Fluores-
cence data from the wild type and K422A forms of
the protein indicate that both adopt a folded confor-
mation when purified and react in an identical fashion
upon denaturation. It is also notable that the K422A
mutant protein displayed a similar pattern of cellular
localization compared with wild type MASL1, suggest-
ing that the nucleotide binding dead form of the pro-
tein is not destabilized to the point where it is targeted
for degradation. One possible consequence of amino
acid substitutions impacting on active site binding such
as the K422A mutation is an increased co-expression
of chaperones such as HSP60 in order to aid protein
folding. However, when co-immunoprecipitation of
HSP60 was examined no significant difference was
observed between wild type and K422A MASL1, sug-
gesting that the lysine to alanine mutation at 422 does
not destabilize the protein.
The paucity of data relating to MASL1 precludes
direct comparisons with other MASL1 studies. Such
comparisons are possible, however, with the other
members of the ROCO protein family – providing an
opportunity to examine whether MASL1 shares fea-
tures with its close paralogues. A number of studies
have demonstrated that there is a close link between
the enzymatic function or nucleotide binding of the
ROCO proteins and the complexes that they form,
and that a disruption of guanosine nucleotide binding
can impair dimerization as is the case for LRRK2
[17,25]. In contrast to LRRK2, loss of guanosine
nucleotide binding does not appear to disrupt dimer-
ization of DAPK1 but more probably controls the
equilibrium between dimeric or multimeric forms of
DAPK1 or controls recruitment of cofactors [10,12].
The SEC data from the experiments described above
reveal that MASL1 can be found in two distinct com-
plexes, one of ~ 600 kDa and a smaller one with an
apparent molecular mass of ~ 200 kDa (Fig. 3). While
both wild type and mutant forms of MASL1 eluted at
~ 600 kDa, only the wild type form of MASL1 (i.e.
able to bind guanosine nucleotides) eluted at
~ 200 kDa. Although the precise nature of the two
complexes remains to be determined, these data sup-
port a model where the LMW complex represents
monomeric MASL1 associated with a binding partner/
partners of approximately 50–80 kDa, as a dimeric
MASL1 complex should migrate at a higher apparent
molecular mass of > 220 kDa. These data appear to
conflict with a recent model for ROCO protein func-
tion [26]; however, an important caveat to the data
reported above is the low resolution of both SEC and
BN analyses of cellular complexes and so it is impossi-
ble to exclude the possibility that this lower peak con-
sists in part of dimeric MASL1. This highlights the
need to derive more detailed structural information for
the ROCO proteins, including MASL1.
An affinity purification coupled with mass spectrom-
etry analysis revealed that MASL1 strongly interacts
with HSP60. Although the interaction could be influ-
enced by the overexpression of MASL1, this result
suggests that MASL1 probably requires the aid of
chaperones to be correctly folded. It is noteworthy
that LRRK2 has been shown to interact with a chap-
erone, HSP90, and disruption of this interaction
results in substantial loss of LRRK2 stability [27].
Further studies are required to determine whether
additional interacting proteins are responsible for the
observed complex formation between wild type and
the nucleotide binding dead form of MASL1.
Very little is known about the cellular role of
MASL1. Two recent publications have highlighted a
potential role in regulating inflammatory response, and
data from both DAPK1 and LRRK2 suggest that
these proteins may be involved in pathways regulating
cell death/proliferation. In light of the link between
MASL1 and cancer, the ability of this protein to bind
guanosine nucleotides (and the impact of this upon its
biology and the complexes that MASL1 forms) may
be important for processes such as proliferation, cell
death or inflammatory signalling. Based upon previous
experiments linking ROC domain biology to the toxic-
ity of LRRK2 and DAPK1, the impact of overexpress-
ing MASL1 and the K422A mutant of MASL1 was
evaluated. Wild type MASL1 displayed a cytotoxic
impact in HEK293T cells as measured by MTT assay
– a toxicity that was accentuated to a small but signifi-
cant extent by the loss of guanosine nucleotide bind-
ing. These data are in contrast to results for LRRK2
and DAPK1, where loss of guanosine nucleotide bind-
ing decreases the cytotoxic phenotype observed upon
overexpression of these proteins. This result was fur-
ther supported by data from FACS analysis of trans-
fected cells. Following on from these data, it is
noteworthy that the cell death induced by MASL1
expression is almost exclusively necrotic, providing a
potential insight into the pathways that MASL1 is
involved in. Although expression of wild type MASL1
alone results in cytotoxicity (as is observed for both
LRRK2 and DAPK1), these data support a role for
the switch from GTP to GDP active site occupancy in
modulating this toxic impact, with loss of guanine
nucleotide binding (and shift to the higher molecular
mass complex) accentuating toxicity.
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Taken together, the data from this study are consis-
tent with a model for MASL1 function where guanosine
nucleotide binding/occupancy controls complex forma-
tion and the downstream consequences of MASL1
activity (Fig. 9). Based upon the conserved role of gua-
nosine nucleotide binding proteins as molecular switches
within the cell, MASL1 may act to regulate cell death/
proliferation based upon its GTP binding. One potential
scenario is that the GTP-bound state represents the ‘on’,
or active, state with MASL1 competent to bind its cellu-
lar effector(s), while losing the affinity for its effector in
the GDP-bound ‘off’ state results in accumulation
within the HMW pool. In this scenario, the HMW com-
plex could represent an inactive, readily releasable pool
of oligomeric MASL1. Future information on the
identity of effector proteins/binding partners could pro-
vide important clues to the physiological function of
MASL1, as well as presenting opportunities to test
whether the model in Fig. 9 is correct. For example, the
identification of candidate guanine nucleotide exchange
factors or GTPase activating proteins that interact with
MASL1 may shed light on how the transition from one
complex to another is managed within the cell. It should
be noted, however, that basal toxicity is observed
independent of alterations in the ROC domain of
MASL1, and it is possible that cytoxicity linked to
MASL1 does not rely on the GTP/GDP-bound status
of the holoprotein and is independent of the ROC
domain. Further investigations into MASL1 function
will reveal which scenario is correct.
With regard to the cellular role of MASL1, it is of
interest that a subset of human leucine-rich repeat
proteins function as pathogen responsive genes in pri-
mary macrophages, and MASL1 in particular was
shown to regulate Toll-like receptor signalling and the
Raf/MEK/ERK signalling pathway in CD34(+) cells
[28,29]. As LRRK2 has also been robustly linked to
immune function [30–32], one intriguing possibility is
that immune response regulation represents a converg-
ing function of human ROCO proteins and that alter-
ation of their immune-related function (i.e. mutations)
leads to disease [33].
In summary, the data presented in this study repre-
sent the first report of the biochemical and cellular
properties of MASL1. The results demonstrate that
MASL1 is a GTP binding protein and that its GTP
binding properties act to regulate complex formation
and cytotoxicity ex vivo. Further studies are required
to determine the exact pathways that this protein is
involved in, and to understand its basic cellular func-
tion and possible contribution towards pathology.
Importantly, a more detailed understanding of this so
far little studied protein has the potential to contribute
to a greater comprehension of how the ROCO pro-
teins function in a cellular context.
Materials and methods
Constructs
HA and FLAG epitope tagged wild type MASL1 constructs
were obtained from Genecopoeia (http://www.genecopoe
ia.com). To generate mutant forms of MASL1 site directed
mutagenesis was carried out using the QuikChange II
mutagenesis kit (Agilent, Santa Clara, CA, USA) according
to the manufacturer’s instructions. Constructs were sequen-
ced prior to use and primer sequences used for the
mutagenesis are available from the authors upon request.
Cell culture and MASL1 expression
HEK293T cells were obtained from ATCC (line identifier
CRL-1573) and grown under standard tissue culture
conditions at 37 °C in 5% CO2 in DMEM (Life Technologies,
Grand Island, NY, USA) supplemented with 10% fetal bovine
serum (Life Technologies). To transfect cells 20 lg of
plasmid DNA was dissolved in 500 lL DMEM before 40 lL
Fig. 9. Complex formation, nucleotide binding and interactors – a
working model for MASL1. The exact biological function of MASL1
is currently unknown. The data included in this study describe
basic MASL1 biochemical properties such as GTP binding, complex
formation and possible interactors. Based on this work a
hypothetical model for MASL1 can be proposed. MASL1, like GTP
binding proteins in general, can be found in two conformational
states, one being ‘on’ (GTP bound) and the other ‘off’ (GDP
bound). This model proposes that MASL1 in the ‘on’ state impacts
upon a binding partner/interactor (possibly including HSP60) via an
effector domain such as a kinase domain.
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polyethylenimine (PEI, Polysciences, Warrington, PA, USA)
was added and the solution was mixed and left to incubate
for a minimum of 15 min at room temperature. The DNA/
PEI solution was then added to cells in 10–15 cm Petri dishes
with experimental procedures being carried out 48 h thereaf-
ter. PEI solution treated HEK293T cells were used through-
out this study as control samples. All incubations, washes
and other treatments were kept consistent between MASL1
and control samples.
GTP pulldown assay
Forty-eight hours after transfection HEK293T cells were
washed twice with ice-cold phosphate buffered saline (NaCl/
Pi) prior to lysis. This was achieved by harvesting cells in cell
lysis buffer (Cell Signaling Technology, Danvers, MA, USA)
containing 1 9 complete protease inhibitor cocktail (Roche,
Indianapolis, IN, USA). Subsequently cell lysates were
rotated for 30 min at 4 °C and then spun at 10 000 g for
10 min to remove cell debris. Next cell lysates were incubated
with 35 lL sepharose beads for 30 min at 4 °C and rotation.
Finally, cell lysates were again centrifuged at 10 000 g, 4 °C
for 10 min to remove sepharose beads, with the clarified
lysates used in subsequent experiments. GTP-conjugated
sepharose beads (Sigma, St Louis, MO, USA) were washed
with lysis buffer and incubated for 1 h at 4 °C and rotation
with 0.1 mgmL1 BSA. GTP beads were then added to cell
lysates for 2 h at 4 °C and rotation  10 mM GTP (Sigma)
before beads were washed three times with lysis buffer and
denatured in 4 9 SDS loading buffer (NuPage SDS sample
buffer, Life Technologies) with 5% b-mercaptoethanol at
100 °C for 10 min. Denatured samples were loaded onto
4–12% Bis Tris gels (Life Technologies). Simultaneously, to
verify MASL1 expression 10 lg per sample as determined by
bicinchoninic acid assay (ThermoFisher, Rockland, IL, USA)
according to the manufacturer’s instructions were also loaded
onto Bis Tris gels (Life Technologies). Proteins were then
transferred to poly (vinylidene difluoride) membrane (Milli-
pore, Billerica, MA, USA), blocked with 5% milk in NaCl/
Pi-Tween (NaCl/Pi + 1% Tween-20) and probed with pri-
mary antibodies at 4 °C overnight (1 : 2000 rat anti-HA,
Roche; 1 : 5000 mouse anti-b-actin, Sigma). The next day
membranes were washed three times in NaCl/Pi-Tween and
incubated for 1 h with secondary antibodies in 5% milk in
NaCl/Pi-Tween at room temperature followed by another
three washes and incubation with Pierce ECL substrate.
Finally membranes were exposed to Kodak biomax films
(Kodak, Rochester, NY, USA) and developed on a Kodak
developer according to the manufacturer’s instructions.
GTPase assay
Cell lysis was carried out as described above with cell lysis
buffer (Cell Signaling Technology). Wild type MASL1,
K422A MASL1 and RAC1 supernatants were incubated
with anti-FLAG beads (Sigma) overnight at 4 °C. The next
day beads were washed 2 9 in each of five wash buffers
(20 mM Tris, 150–500 mM NaCl, 0.02–1% Triton X-100)
before being eluted in elution buffer (20 mM Tris, 150 mM
NaCl, 0.02% Triton X-100) with 150 nglL1 FLAG pep-
tide (Sigma) for 45 min at 4 °C. Eluted protein was then
incubated with assay buffer (20 mM Hepes, pH 7.2, 2 mM
MgCl2, 1 mM dithiothreitol and 0.05% BSA) and [a
32P]
GTP (5 lCi; Perkin Elmer, Waltham, MA, USA) was
added to each reaction. Samples were incubated at 37 °C
with vigorous shaking and 2 lL aliquots were removed at
time points from 0 to 120 min and spotted onto TLC
plates (Sigma). Samples were then subjected to rising TLC
under 1 M formic acid and 1.2 M LiCl. After drying the
plates they were exposed to Kodak biomax films overnight
and developed the following day using a Kodak developer.
The remaining samples were denatured, run on SDS/
PAGE, transferred onto poly(vinylidene difluoride) mem-
branes and immunoblotted as described above.
Intrinsic fluorescence
Fluorescence emission spectra were recorded on a Cary
Eclipse fluorescence spectrophotometer (Agilent Technolo-
gies) using the Cary Eclipse program. Sample measure-
ments were carried out using an optical path length of
10 mm. Fluorescence spectra were obtained using an exci-
tation wavelength of 288 nm, with an excitation bandwidth
of 5 nm. Emission spectra were recorded between 300 and
400 nm at a scan rate of 30 nms1. Spectra were acquired
using 100 nM proteins in 20 mM Tris/HCl buffer (pH 7.5),
150 mM NaCl and 0.02% Tween-20.
Immunocytochemistry
To visualize expression of MASL1, transfected HEK293T
cells were grown on glass coverslips (VWR, Radnor, PA,
USA) for 48 h after transfection before being fixed with
4% PFA at room temperature for 10 min. Fixed cells were
then blocked for 30 min in 15% normal goat serum (NGS)
in NaCl/Pi + 0.1% Triton X-100 before incubation with
primary antibodies in 10% NGS in NaCl/Pi + 0.1% Triton
X-100 (1 : 2000 rat anti-HA, Roche; 1 : 1000 mouse anti-
LAMP1; 1 : 500 rabbit anti-complex V) at 4 °C overnight.
Next cells were incubated with fluorescently labelled sec-
ondary antibodies in 10% NGS in NaCl/Pi + 0.1% Triton
X-100 (goat anti-rat 488, goat anti-mouse IgG1 568; goat
anti-rabbit 568) before being counterstained with DAPI at
1 : 2000 in NaCl/Pi. To detect F-actin Alexa Fluor
 633
phalloidin was used at 1 : 300 (Life Technologies) before
cells were mounted onto uncoated glass slides (VWR) using
Fluoromount G mounting medium (Southern Biotech,
Birmingham, AL, USA). Images were obtained on an
LSM 710 confocal microscope and compiled using Adobe
Photoshop.
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Size exclusion chromatography
MASL1 transfected HEK293T cell lysates obtained as
described above were injected and separated on a Superose 6
10/300 column (GE Healthcare, Little Chalfont, Buckin-
ghamshire, UK). The column was pre-equilibrated with
buffer (20 mM Tris/HCL, pH 7.5, 150 mM NaCl and 0.07%
Tween-20 or with the same buffer containing 200 lM GTP,
GDP or GMppCp) and used at a flow rate of 0.5 mLmin1.
Elution volumes of standards were 12 mL for thyreoglobin
(669 kDA), 14 mL for ferritin (440 kDA), 15.5 mL for cata-
lase (232 kDA) and 17 mL for aldolase (158 kDA). Elution
fractions were collected and analysed using dot blots. For
the analysis in the presence of guanosine nucleotides the
Superose 6 10/300 column was pre-equilibrated with buffer
(as mentioned above) containing 200 lM GTP, GDP or
GMppCp for 60 min. Cell lysates were incubated with the
same concentration of nucleotides prior to analysis by SEC.
Dot blot
1 lL of each collected SEC fraction was spotted onto a
nitrocellulose membrane. Once dried the membrane was
blocked in NaCl/Pi-Tween with 5% milk for 1 h before
being incubated with 1 : 2000 rat anti-HA and secondary
anti-rat (Sigma) both in 5% milk. Membranes were then
developed as described above.
Mass spectrometry analysis
MS analysis was carried out by the Biological Mass Spec-
trometry Centre at the Institute of Child Health, University
College London (http://www.ucl.ac.uk/ich/services/lab
services/mass_spectrometry). For this analysis MASL1
transfected HEK293T cells were lysed, immunoprecipitated
and washed as described above (GTPase assays) before
denatured samples were loaded and run on 4–12% Bis Tris
gels (Life Technologies), stained with Imperial Protein
Stain (Thermo Scientific) and excised from gels (Fig. 4A)
for MS analysis by MALDI-QTOF MS (Waters Corpora-
tion, Milford, MA, USA).
Cell toxicity assay
Forty-eight hours post-transfection of HEK293T cells with
MASL1 (wild type and mutant forms) MTT (Sigma
Aldrich) was added at a final concentration of 500 lgmL1
for 3 h. The medium was then discarded before formazan
crystals, accumulated within energetically active cells, were
dissolved in pure dimethylsulfoxide. The assay was carried
out in 96-well plates, which were then analysed in a multi-
well plate reader measuring the absorbance of every single
well at a wavelength of 570 nm. Results are shown as
percentage cell viability after transfection in comparison
with transfection reagent only treated cells.
Fluorescence-activated cell sorting
To establish cellular toxicity of wild type and K422AMASL1
in HEK293T cells an apoptotic/necrotic/healthy cells
detection kit (Promokine, Heidelberg, Germany) was used,
following the manufacturer’s instructions. To detect MASL1
transfected cells a fluorescently labelled FLAG-tag antibody
(DYKDDDDK-tag antibody, Alexa Fluor 647 conjugate;
Cell Signaling) was used. Cells were stained for 30 min in
NaCl/Pi containing 0.1% Triton X-100 with FLAG-tag anti-
body at 1 : 500. Post staining cells were resuspended in cold
NaCl/Pi containing 0.1 mM EDTA to minimize clumping
and passed through a cell strainer (70 lm) (BD Biosciences,
San Jose, CA, USA). Cells were sorted on a BD Bioscience
FACS LSRII running FACSDIVA6.3 software. Fluorescently
labelled cells were excited using the red laser (560 nm), with
emission analysed using the PE PMT via a 505 long pass and
525/50 band pass filter, the green laser (488 nm) and analysed
using the FITC PMT via a 505 long pass and a 525/50 band
pass filter, or a violet (405 nm) laser and the Pacific Blue
PMT with a 450/50 band pass filter. Debris, doublets and
dead cells were excluded from analysis (Fig. 8, p2 represents
all cells analysed). Approximately 27 000 FLAG positive
cells were analysed for both wild type and K422AMASL1.
Statistical analysis
SPSS software (IBM, Armonk, NY, USA) was used for sta-
tistical comparison. To assess potential significant differ-
ences one-way analysis of variance analysis (ANOVA) with
Bonferroni post hoc correction was used. Significance was
considered to be < 0.05.
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